2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic-acid and Obesity

2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic-acid has been researched along with Obesity* in 2 studies

Other Studies

2 other study(ies) available for 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic-acid and Obesity

ArticleYear
Tissue-specific postprandial clearance is the major determinant of PPARgamma-induced triglyceride lowering in the rat.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 296, Issue:1

    Peroxisome proliferator-activated receptor-gamma (PPARgamma) agonism potently reduces circulating triglycerides (TG) in rodents and more modestly so in humans. This study aimed to quantify in vivo the relative contribution of hepatic VLDL-TG secretion and tissue-specific TG clearance to such action. Rats were fed an obesogenic diet, treated with the PPARgamma full agonist COOH (30 mg.kg(-1).day(-1)) for 3 wk, and studied in both the fasted and refed (fat-free) states. Hepatic VLDL-TG secretion rate was not affected by chronic COOH in the fasted state and was only modestly decreased (-30%) in refed rats. In contrast, postprandial VLDL-TG clearance was increased 2.6-fold by COOH, which concomitantly stimulated adipose tissue TG-derived lipid uptake and one of its major determinants, lipoprotein lipase (LPL) activity, in a highly depot-specific manner. TG-derived lipid uptake and LPL were indeed strongly increased in subcutaneous inguinal white adipose tissue and in brown adipose tissue, independently of the nutritional state, whereas of the three visceral fat depots examined (epididymal, retroperitoneal, mesenteric) only the latter responded consistently to COOH. Robust correlations (0.5 < r < 0.9) were observed between TG-derived lipid uptake and LPL in adipose tissues. The agonist did not increase LPL in muscle, and its enhancing action on postprandial muscle lipid uptake appeared to be mediated by post-LPL processes involving increased expression of fatty acid binding/transport proteins (aP2, likely in infiltrated adipocytes, FAT/CD36, and FATP-1). The study establishes in a diet-induced obesity model the major contribution of lipid uptake by specific, metabolically safe adipose depots to the postprandial hypotriglyceridemic action of PPARgamma agonism, and suggests a key role for LPL therein.

    Topics: Acetates; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Down-Regulation; Eating; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Glycerol; Hypolipidemic Agents; Indoles; Insulin; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Male; Muscle, Skeletal; Nutritional Status; Obesity; Postprandial Period; PPAR gamma; Rats; Rats, Sprague-Dawley; Time Factors; Triglycerides

2009
Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
    The Journal of pharmacology and experimental therapeutics, 2005, Volume: 314, Issue:1

    Insulin resistance clusters with hyperlipidemia, impaired glucose tolerance, and hypertension as metabolic syndrome X. We tested a low molecular weight insulin receptor activator, demethylasterriquinone B-1 (DMAQ-B1), and a novel indole peroxisome proliferator-activated receptor gamma agonist, 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid (PPEIA), in spontaneously hypertensive obese rats (SHROB), a genetic model of syndrome X. Agents were given orally for 19 days. SHROB showed fasting normoglycemia but impaired glucose tolerance after an oral load, as shown by increased glucose area under the curve (AUC) [20,700 mg x min/ml versus 8100 in lean spontaneously hypertensive rats (SHR)]. Insulin resistance was indicated by 20-fold excess fasting insulin and increased insulin AUC (6300 ng x min/ml versus 990 in SHR). DMAQ-B1 did not affect glucose tolerance (glucose AUC = 21,300) but reduced fasting insulin 2-fold and insulin AUC (insulin AUC = 4300). PPEIA normalized glucose tolerance (glucose AUC = 9100) and reduced insulin AUC (to 3180) without affecting fasting insulin. PPEIA also increased food intake, fat mass, and body weight gain (81 +/- 12 versus 45 +/- 8 g in untreated controls), whereas DMAQ-B1 had no effect on body weight but reduced subscapular fat mass. PPEIA but not DMAQ-B1 reduced blood pressure. In skeletal muscle, insulin-stimulated phosphorylation of the insulin receptor and insulin receptor substrate protein 1-associated phosphatidylinositol 3-kinase activity were decreased by 40 to 55% in SHROB relative to lean SHR. PPEIA, but not DMAQ-B1, enhanced both insulin actions. SHROB also showed severe hypertriglyceridemia (355 +/- 42 mg/dl versus 65 +/- 3 in SHR) attenuated by both agents (DMAQ-B1, 228 +/- 18; PPEIA, 79 +/- 3). Both these novel antidiabetic agents attenuate insulin resistance and hypertriglyceridemia associated with metabolic syndrome but via distinct mechanisms.

    Topics: Acetates; Adipose Tissue; Animals; Blood Pressure; Body Weight; Eating; Female; Glucose Tolerance Test; Hyperinsulinism; Indoles; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Obesity; Phosphatidylinositol 3-Kinases; Phosphoproteins; PPAR gamma; Rats; Rats, Inbred SHR; Receptor, Insulin; Signal Transduction

2005